Nice list Kelsee. That pretty much covers the big ones. You stated ".....when will the other trials launch." I assume you are referring to the Renal/Dialysis and Fabry trials that have been approved for some time now and listed on ClinicalTrials.gov.

My only other comments are related to other planned or on-hold clinical trials and molecules that have been mentioned in the past. 

What is the latest update on the apabetalone pre-clinical program, collaboration, manuscript and potential trial for Pulmonary Arterial Hypertension?

What is the latest on the complement disease clinical program for PNH (Paroxysmal Nocturnal Hemoglobinuria) or other similar complement-related disease?

Any plans for clinical development of apabetalone for HIV-1 Latency?

Any interested parties contact Resverlogix in regards to a collaboration related to the latest colorectal cancer metastasis paper?

What is the latest on Muscular Dystrophy/Facio Scapulo Humeral Dystrophy pre-clinical program for alleviating symptoms of these muscle diseases? Has an alternative muscle delivery approach been found to get more of the compound to the affected muscle area?

Resverlogix previously “confirmed” a second clinical compound IND candidate and informed us that seven compounds have been chosen for follow-on testing (including RVX-206, RVX-641, RVX-2101, RVX-2113). What differentiates these seven additional compounds from apabetalone and what are the plans?

Management has previously mentioned in past presentations additional indications such as: Neurofibromatosis/Malignant Peripheral Nerve Sheath Tumors (MPNST), Calciphylaxis/Calcification, Autoimmune. For these and the other pre-clinical programs listed above, what is the most advanced and promising of the pre-clinical programs (aside from Renal and Fabry that already have trials listed on ClinicalTrials.gov)?

BearDownAZ